Comments on: Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting - kaiyun体育全站入口
//www.yitiaoweiba.com/en/junshi-biosciences-announces-updated-clinical-data-from-phase-i-study-of-anti-btla-antibody-tifcemalimab-in-treatment-of-relapsed-refractory-lymphomas-at-64th-ash-annual-meeting/
创新疗法的发现、开发和商业化的生物制药公司。Thu, 04 May 2023 10:31:25 +0000
hourly
1 https://wordpress.org/?v=6.7.3